ProQR Therapeutics N.V (NASDAQ:PRQR) shares, rose in value, with the stock price down by -1.97% to the previous day’s close as strong demand from buyers drove the stock to $1.49.
Actively observing the price movement in the recent trading, the stock is buoying the session at $1.52, falling within a range of $1.46 and $1.54. The value of beta (5-year monthly) is 0.24. Referring to stock’s 52-week performance, its high was $4.62, and the low was $1.50. On the whole, PRQR has fluctuated by -37.92% over the past month.
With the market capitalization of ProQR Therapeutics N.V currently standing at about $156.76 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-12.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 4.9M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that PRQR’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of PRQR currently trading nearly -16.83% and -28.84% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 22.67, while the 7-day volatility ratio is showing 5.25% which for the 30-day chart, stands at 6.62%. Furthermore, ProQR Therapeutics N.V (PRQR)’s beta value is 0.16, and its average true range (ATR) is 0.12.
A comparison of ProQR Therapeutics N.V (PRQR) with its peers suggests the former has fared considerably weaker in the market. PRQR showed an intraday change of -1.97% in today’s session so far, and over the past year, it shrunk by -37.66%%.
Data on historical trading for ProQR Therapeutics N.V (NASDAQ:PRQR) indicates that the trading volumes over the past 10 days have averaged 0.77 and over the past 3 months, they’ve averaged 427.50K. According to company’s latest data on outstanding shares, there are 102.71 million shares outstanding.
Nearly 32.74% of ProQR Therapeutics N.V’s shares belong to company insiders and institutional investors own 42.32% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.02 million shares as on 2025-03-14, resulting in a short ratio of 2.51. According to the data, the short interest in ProQR Therapeutics N.V (PRQR) stood at 137.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 0.97 million. The stock has fallen by -43.77% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PRQR stock heading into the next quarter.
